Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

HeartWare Intl. To Buy World Heart For $8 Mln

RELATED NEWS
Trade HTWR now with 

HeartWare International, Inc. (HTWR: Quote), which develops and manufactures miniaturized ventricular assist devices, said Thursday that it has agreed to buy World Heart Corp. (WHRT: Quote), which has been engaged in the development of left ventricular assist devices, for consideration of US$8 million, which will be paid in shares of HeartWare common stock or cash, at HeartWare's election.

The per share merger consideration will be determined by dividing $8 million by the number of shares of WorldHeart common stock outstanding on a fully diluted basis, or about $0.29 per share at today's fully diluted WorldHeart common stock outstanding.

The boards of directors of both companies have approved the deal, which is subject to the approval of WorldHeart's stockholders and satisfaction of other customary closing conditions. HeartWare stockholder approval is not required.

The deal is expected to close within about 90 days.

Click here to receive FREE breaking news email alerts for HeartWare International Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.